Patient Preference and Adherence (Aug 2023)

Awareness of HBV Functional Cure and Attitude Toward Related Clinical Trials Among Patients with Chronic Hepatitis B in China

  • Duan Z,
  • Dong J,
  • Liu Y,
  • Zhou H,
  • Duan S,
  • Liu W,
  • Liang R,
  • Ding Y

Journal volume & issue
Vol. Volume 17
pp. 2063 – 2072

Abstract

Read online

Zhongping Duan,1 Jinling Dong,1 Ying Liu,2 Haiyang Zhou,2 Shuli Duan,2 Weihong Liu,3 Rico Liang,3 Yue Ding3 1Fourth Department of Hepatology Center, Beijing You’an Hospital, Capital Medical University, Beijing, People’s Republic of China; 2iGandan, the Portal for All Liver Disease Caring, Beijing, People’s Republic of China; 3Brii Biosciences Inc., Beijing, People’s Republic of ChinaCorrespondence: Rico Liang, Brii Biosciences Inc, 3F, Building 7, Zhongguancun Dongsheng International Science Park, No. 1 North. Yongtaizhuang Road, Haidian District, Beijing, 100192, People’s Republic of China, Tel/Fax +86 10 6587 6121, Email [email protected]: HBV functional cure is an optimal treatment goal for chronic hepatitis B (CHB) at present and numerous new drugs aiming for HBV functional cure are in development. We carried out an internet-based survey to understand the treatment status, unmet needs, awareness of HBV functional cure and attitude toward related clinical trials among CHB patients in China.Patients and Methods: An internet-based anonymous survey was conducted on CHB patients who reside in mainland China. Determinants of awareness and attitude were identified by logistic regression models.Results: Of the 1220 CHB patients who completed the survey questionnaire, 11.1% (135/1220) were aware of HBV functional cure and 50.2% (612/1220) answered “definitely will” to participate in related clinical trials. Participants who knew their HBsAg level (HBsAg< 1500 IU/mL: OR=3.03, 95% CI: 1.87– 4.92; HBsAg≥ 1500 IU/mL: OR=2.57, 95% CI: 1.35– 4.88), who expected to achieve HBsAg loss with treatment (OR=1.63, 95% CI: 1.07– 2.50) and who were dissatisfied with current treatment due to the failure of achieving HBsAg loss (OR=1.67, 95% CI: 1.10– 2.53) had better awareness of HBV functional cure. Participants who had HBsAg level less than 1500 IU/mL (OR=1.45, 95% CI: 1.05– 1.99), treatment with pegylated interferon alpha with or without nucleos(t)ide (OR=1.68, 95% CI: 1.11– 2.53) and better awareness of HBV functional cure (OR=1.62, 95% CI: 1.01– 2.61) were more likely to say “definitely will” to participate in related clinical trials.Conclusion: Chinese CHB patients reported a low awareness of HBV functional cure. Although CHB patients in China reported a low rate of HBV functional cure awareness, they had a high acceptance of related clinical trials.Keywords: CHB, HBV functional cure, awareness, related clinical trials

Keywords